Eli Lilly and Company (NYSE:LLY) Increases Dividend to $1.73 Per Share

Eli Lilly and Company (NYSE:LLY) declared a quarterly dividend on Monday, December 8th. Stockholders of record on Friday, February 13th will be paid a dividend of 1.73 per share on Tuesday, March 10th. This represents a c) annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Friday, February 13th. This is a 15.3% increase from Eli Lilly and Company’s previous quarterly dividend of $1.50.

Eli Lilly and Company has increased its dividend by an average of 0.2%per year over the last three years and has raised its dividend annually for the last 11 consecutive years. Eli Lilly and Company has a payout ratio of 20.2% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Eli Lilly and Company to earn $31.12 per share next year, which means the company should continue to be able to cover its $6.00 annual dividend with an expected future payout ratio of 19.3%.

Eli Lilly and Company Stock Down 1.5%

Shares of LLY opened at $995.63 on Tuesday. The company has a market capitalization of $941.25 billion, a price-to-earnings ratio of 48.71, a PEG ratio of 1.12 and a beta of 0.37. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,111.99. The stock’s 50-day moving average price is $924.25 and its 200-day moving average price is $812.32. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.Eli Lilly and Company’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same period in the previous year, the company posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Painted Porch Advisors LLC grew its stake in Eli Lilly and Company by 125.7% during the 3rd quarter. Painted Porch Advisors LLC now owns 79 shares of the company’s stock valued at $60,000 after acquiring an additional 44 shares in the last quarter. Strategic Investment Solutions Inc. IL boosted its holdings in shares of Eli Lilly and Company by 1.6% during the 3rd quarter. Strategic Investment Solutions Inc. IL now owns 741 shares of the company’s stock worth $565,000 after purchasing an additional 12 shares during the last quarter. Severin Investments LLC grew its position in shares of Eli Lilly and Company by 19.1% in the third quarter. Severin Investments LLC now owns 680 shares of the company’s stock valued at $519,000 after purchasing an additional 109 shares in the last quarter. Allworth Financial LP increased its holdings in shares of Eli Lilly and Company by 9.2% in the third quarter. Allworth Financial LP now owns 62,578 shares of the company’s stock valued at $47,747,000 after purchasing an additional 5,249 shares during the last quarter. Finally, IFP Advisors Inc lifted its position in Eli Lilly and Company by 13.2% during the third quarter. IFP Advisors Inc now owns 17,615 shares of the company’s stock worth $13,445,000 after buying an additional 2,057 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.